Skip to content

Exelixis, Inc. (EXEL) stock: revenue, earnings & dividend

Exelixis, Inc. (EXEL, Nasdaq): revenue, earnings, dividend and balance sheet from official SEC filings.

Stock screener EXEL · Nasdaq Pharma & Biotech US-CA

Key figures

Fiscal year
2025
Revenue
2.32 bn $
Revenue growth
7 %
Revenue growth 5y (p.a.)
18.6 %
Net income
783 m $
Net margin
33.7 %
Operating margin
37.6 %
Earnings per share (diluted)
2.78 $
Dividend per share
–
Payout ratio
–
Consecutive dividend years
–
Consecutive dividend raises
–
Dividend growth 5y (p.a.)
–
Total assets
2.84 bn $
Equity
2.16 bn $
Equity ratio
76 %
Return on equity
36.2 %
Cash
482 m $
Operating cash flow
884 m $
Free cash flow
876 m $
Shares outstanding
244,010,895

History

Revenue by fiscal year

2016 191 m $
2017 452 m $
2018 854 m $
2019 968 m $
2020 988 m $
2021 1.43 bn $
2022 1.61 bn $
2023 1.83 bn $
2024 2.17 bn $
2025 2.32 bn $

Net income by fiscal year

2016 -70.22 m $
2017 154 m $
2018 690 m $
2019 321 m $
2020 112 m $
2021 231 m $
2022 182 m $
2023 208 m $
2024 521 m $
2025 783 m $
YearRevenueNet incomeEPSDividend per shareOperating cash flow
20252.32 bn $783 m $2.78 $–884 m $
20242.17 bn $521 m $1.76 $–700 m $
20231.83 bn $208 m $0.65 $–333 m $
20221.61 bn $182 m $0.56 $–363 m $
20211.43 bn $231 m $0.72 $–401 m $
2020988 m $112 m $0.35 $–209 m $
2019968 m $321 m $1.02 $–527 m $
2018854 m $690 m $2.21 $–416 m $
2017452 m $154 m $0.49 $–166 m $
2016191 m $-70.22 m $-0.28 $–206 m $

Data from XBRL filings at the SEC, processed automatically, no guarantee. Not investment advice. All filings at the SEC (EDGAR)